NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-31
Reading ALKS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue growth is accelerating — up about 11% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 40% growth a year, above the roughly 11% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAlkermes aims to drive revenue growth amid a CEO transition and positive pipeline developments. Recent earnings showed a 27% revenue increase, and the last quarter beat expectations. The stock trades at 27× P/E, above the peer median of 14.5×, indicating high expectations. Risks include a 31% chance of missing future earnings guidance. Peer multiples imply a price about 43% below where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-07-31. ALKS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering ALKS (as of Jul 2026).
Based on 5 Wall Street analysts offering 12-month price targets for ALKS in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Advances: Drive revenue growth
Revenue guidance supports growth objectives amid CEO transition.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $48.99
The last 12 months of price, then the range of analyst 12-month targets from today’s $48.99.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase revenue growth
Price target increase indicates confidence in revenue growth.
Advances: Advance LUMRYZ for idiopathic hypersomnia
Positive data supports LUMRYZ for idiopathic hypersomnia.
Advances: Advance LUMRYZ for idiopathic hypersomnia
Advances LUMRYZ development, aligning with management's objectives.
Advances: Increase revenue growth
Positive earnings outlook supports revenue growth objective.
Advances: Increase revenue growth
Highlights growth potential, aligns with revenue growth objective.
Advances: Increase revenue growth
Momentum stock status supports revenue growth objective.
